Our study provides unprecedented insight into the role of a novel biomarker of AD clinical dementia, and allow for the further systematic investigation of a potential novel therapeutic role for S100A7 via promotion of “non-amyloidogenic” α-secretase/ADAM-10 mediated responses and possibly through other mechanisms presently under investigation in our laboratory. This evidence concerns the gene S100A7 and Alzheimer disease.